Table 3.
Baseline clinical and laboratory characteristics by quartile of FT4
| I | II | III | IV | P | |
|---|---|---|---|---|---|
| Number |
111 |
111 |
112 |
112 |
/ |
| Age (years) |
65.2 ± 16.7 |
69.4 ± 15.6 |
71.3 ± 15.1 |
70.3 ± 14.4 |
0.020 |
| Men, Number (%) |
65 (58.6) |
67 (60.4) |
72 (64.3) |
56 (50.0) |
0.171 |
| APACHE-II score (points) |
15.6 ± 7.3 |
15.1 ± 7.9 |
14.9 ± 6.7 |
16.3 ± 7.4 |
0.524 |
| Baseline Scr (umol/L) |
80.0 ± 45.9 |
80.0 ± 39.0 |
86.6 ± 46.4 |
84.0 ± 48.7 |
0.636 |
| Current Scr (umol/L) |
98.2 ± 89.4 |
100.7 ± 61.5 |
108.1 ± 79.7 |
106.8 ± 76.1 |
0.741 |
| Cysc (mg/L) |
1.23 ± 0.65 |
1.23 ± 0.51 |
1.32 ± 0.67 |
1.35 ± 0.79 |
0.354 |
| Albumin (g/L) |
32.7 ± 4.7 |
35.0 ± 6.1 |
35.1 ± 5.0 |
35.4 ± 5.5 |
0.000 |
| TT3 (nmol/L) |
0.83 ± 0.39 |
0.94 ± 0.34 |
0.89 ± 0.29 |
0.90 ± 0.36 |
0.109 |
| TT4 (nmol/L) |
72.04 ± 28.93 |
89.17 ± 23.00 |
90.03 ± 20.98 |
94.32 ± 24.29 |
0.000 |
| FT3 (pmol/L) |
3.04 ± 0.62 |
3.27 ± 0.54 |
3.42 ± 0.59 |
3.66 ± 0.92 |
0.000 |
| FT4 (pmol/L) |
11.93 ± 1.54 |
14.47 ± 0.53 |
16.14 ± 0.50 |
19.58 ± 3.17 |
0.000 |
| TSH (IU/mL) |
3.87 ± 16.16 |
1.26 ± 1.03 |
1.70 ± 1.84 |
1.14 ± 1.05 |
0.044 |
| rT3 (nmol/L) |
0.49 ± 0.21 |
0.54 ± 0.21 |
0.54 ± 0.24 |
0.57 ± 0.27 |
0.113 |
| AKI (Number, %) | 24 (21.6) | 26 (23.4) | 36 (32.1) | 28 (25.0) | 0.292 |
Quartile cut points for FT4 were 13.49, 15.38 and 17.07 pmol/L, continuous variables were compared with one-way ANOVA, and dichotomous variables were compared with the chi-square test. ANOVA, analysis of variance; APACHE II score, Acute Physiology and Chronic Health Evaluation II score; Baseline Scr, baseline serum creatinine; Current Scr, serum creatinine on the entry to ICU; Cysc, Cystatin C; FT3, free triiodothyronine; FT4, free thyroxine; rT3, reverse triiodothyronine; TSH, thyroid-stimulating-hormone; TT3, total triiodothyronine; TT4, total thyroxine.